skip to main content

Our Team

Nouveau Biosciences is composed of an unprecedented team of leaders combining business, science, and regulatory expertise transforming oncology drug discovery, development and clinical application into approved therapies.

Leadership

Owen A. O’Connor

Owen A. O’Connor, M.D., Ph.D

Chief Executive Officer

LinkedIn

  • American Cancer Society Research Physician

  • Over 30 inventions filed globally

  • 6 drugs approved in 50 countries

  • Prior Chief Scientific Officer at TG Therapeutics

  • Co-founder of Therasis and Nouveau Biosciences

Sloan Kettering
University of Virginia
TG
Columbia University
Thomas Loughran

Thomas Loughran, M.D.

Director, Nanovations

LinkedIn

  • Director of UVA Comprehensive Cancer Center, an NCI Designated Cancer Center

  • Most significantly funded research scientist in the history of the Commonwealth of Virginia

  • Renowned cancer biologist

Penn State
Moffitt
University of Virginia
Saleem Elmasri

Saleem Elmasri, C.P.A.

Chief Financial Officer

  • 20 years of progressive experience in audit, accounting, and finance operations
  • Led or supported over $5b in M&A and IPOs
  • Experience in leading finance organizations for public and private companies
  • Skilled in investor relations and corporate communications
T logo
PWC
Joseph Turgeon

Joseph Turgeon

Chief Operating Officer

  • Ex-CEO Spectrum Pharmaceuticals
  • More than 38 years experience in oncology drug development
  • Part of the original Amgen Team leading their marketing success
AMGEN
Spectrum Pharmaceuticals

Board of Directors

Owen A. O’Connor

Owen A. O’Connor, M.D., Ph.D

Chief Executive Officer

LinkedIn

  • American Cancer Society Research Physician

  • Over 30 inventions filed globally

  • 6 drugs approved in 50 countries

  • Prior Chief Scientific Officer at TG Therapeutics

  • Co-founder of Therasis and Nouveau Biosciences

Sloan Kettering
University of Virginia
TG
Columbia University
Mark Lerner

Mark Lerner, Esq.

Member

  • Trial and employment attorney for over 30 years

  • Past Federal Prosecutor in the U.S. Attorneys Office for the Eastern District of New York

  • Extensive experience litigating complex cases across private equity and health care.

Andrew Pecora

Andrew Pecora, M.D., FACP, CPE

Member

  • Over 30 years experience and international authority in stem cell transplantation

  • Founder of the John Theurer Cancer Center in Hackensack, N.J.

  • More than 25 years experience creating biotechnology companies advancing innovative immunotherapies for the treatment of cancer.

     

Scientific Advisory Board

Howard Burris

Skip Burris, MD, FACP, FASCO

SAB, Board Chair

  • President and Chief Medical Officer of Sarah Cannon Research Institute
  • Executive Director, Drug Development for the research institute.
  • International authority in drug development, clinical trials and regulatory process
  • President Elect of ASCO (2019-2020)

Diane Mould, Ph.D.

Member

  • 30+ years as a pharmacokineticist in industry where she specialized in population pharmacokinetic / pharmacodynamic modeling
  • Extensive experience in filing regulatory applications to FDA
  • Has been involved in countless applications for hematopoietic agents, monoclonal antibodies and anti-cancer therapies

Michael Matiland, M.D.

Member

  • Internationally recognized authority on early phase clinical trial design, pharmacokinetics, Project Optimus, and regulatory strategy
  • Presently VP for Clinical Development at Pathos
  • Previous Medical Lead for CRISPER technologies, Intellia Therapeutics, Inc.
  • Physician Scientist, ASCO Cancer Research Committee
Greg Nowakowski

Greg Nowakowski, M.D.

Member

  • Past voting member and Chair of US FDA Oncology Drug Advisory Committee (ODAC)
  • Deputy Director of Mayo Clinic Comprehensive Cancer Center for Clinical Research
  • Internationally renowned authority on the regulatory approval of drugs for hematologic malignancies and clinical trials